# Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer
Canonical URL: https://biopharmsignal.com/news/AQST/aquestive-therapeutics-announces-new-role-of-lori-j-braender-and-appointment-of-thomas-a-zalewski-as-chief-legal-officer-and-chief-compliance-officer
Ticker: AQST
Company: Aquestive Therapeutics
Source: Aquestive Therapeutics
Published: 2026-03-20 11:00 EST
Original Source URL: https://investors.aquestive.com
## Summary

Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal Officer and Chief Compliance Officer effective April 2, 2026 Lori J. Braender to remain in a non-executive role as Corporate Secretary after nearly eight years as Chief Legal Officer, Chief Compliance Officer and Corporate

## Article Body
Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal Officer and Chief Compliance Officer effective April 2, 2026 Lori J. Braender to remain in a non-executive role as Corporate Secretary after nearly eight years as Chief Legal Officer, Chief Compliance Officer and Corporate
## Recent Company News
- 2026-05-13 20:01 EST — [Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/AQST/aquestive-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Aquestive Therapeutics
- 2026-05-12 13:32 EST — [Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree](https://biopharmsignal.com/news/AQST/aquestive-therapeutics-completes-150-million-debt-refinancing-with-oaktree) — Source: Aquestive Therapeutics
- 2026-05-06 11:00 EST — [Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET](https://biopharmsignal.com/news/AQST/aquestive-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-business-highlights-on-may-13-and-host-conference-call-on-may-14-at-8-00-a-m-et) — Source: Aquestive Therapeutics
- 2026-03-30 11:00 EST — [Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film](https://biopharmsignal.com/news/AQST/aquestive-therapeutics-announces-completion-of-type-a-meeting-with-fda-for-anaphylmtm-dibutepinephrine-sublingual-film) — Source: Aquestive Therapeutics
- 2026-03-20 11:00 EST — [Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer](https://biopharmsignal.com/news/AQST/aquestive-therapeutics-announces-new-role-of-lori-j-braender-and-appointment-of-thomas-a-zalewski-as-chief-legal-officer-and-chief-compliance-officer) — Source: Aquestive Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)